509 related articles for article (PubMed ID: 10079000)
1. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
[TBL] [Abstract][Full Text] [Related]
2. Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1996 Jul; 307(3):259-67. PubMed ID: 8836613
[TBL] [Abstract][Full Text] [Related]
3. Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.
Christophe B; Libon R; Cazaubon C; Nisato D; Manning A; Chatelain P
Eur J Pharmacol; 1995 Aug; 281(2):161-71. PubMed ID: 7589203
[TBL] [Abstract][Full Text] [Related]
4. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens; 2001 Mar; 19(3):465-73. PubMed ID: 11288817
[TBL] [Abstract][Full Text] [Related]
7. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Morita O; Kushida H; Kunihara M
J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
[TBL] [Abstract][Full Text] [Related]
8. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
Bunting MW; Widdop RE
Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
[TBL] [Abstract][Full Text] [Related]
9. The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopressin responses to central angiotensin.
Hogarty DC; Speakman EA; Puig V; Phillips MI
Brain Res; 1992 Jul; 586(2):289-94. PubMed ID: 1521162
[TBL] [Abstract][Full Text] [Related]
10. The selective angiotensin AT1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1995 Apr; 277(2-3):223-8. PubMed ID: 7493612
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II-induced drinking and pressor responses to central or systemic irbesartan and losartan.
Grippo AJ; Kirby RF; Beltz TG; Johnson AK
Pharmacol Biochem Behav; 2002; 71(1-2):139-46. PubMed ID: 11812516
[TBL] [Abstract][Full Text] [Related]
12. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
[TBL] [Abstract][Full Text] [Related]
13. Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats.
Toney GM; Porter JP
Neuropharmacology; 1993 Jun; 32(6):581-9. PubMed ID: 8336821
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.
Polidori C; Ciccocioppo R; Nisato D; Cazaubon C; Massi M
Eur J Pharmacol; 1998 Jul; 352(1):15-21. PubMed ID: 9718262
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Leenen FH; Yuan B
Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
Cazes M; Provost D; Versigny A; Cloarec A
Eur J Pharmacol; 1995 Sep; 284(1-2):157-70. PubMed ID: 8549620
[TBL] [Abstract][Full Text] [Related]
17. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier.
Bui JD; Kimura B; Phillips MI
Eur J Pharmacol; 1992 Aug; 219(1):147-51. PubMed ID: 1397042
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
19. Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats.
Toney GM; Porter JP
Brain Res Dev Brain Res; 1993 Feb; 71(2):193-9. PubMed ID: 8491041
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin AT1 receptor-mediated vasopressin release and drinking are potentiated by an AT2 receptor antagonist.
Höhle S; Spitznagel H; Rascher W; Culman J; Unger T
Eur J Pharmacol; 1995 Mar; 275(3):277-82. PubMed ID: 7768295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
